Newswise — Apheresis, the simple process of drawing blood, becomes a powerful therapeutic in extracorporeal photopherisis (ECP) according to clinicians and scientists who met at the NIH State of the Science Symposium in Therapeutic Apheresis. Nora Ratcliffe, MD, of Dartmouth Hitchcock, looked at current methodology and opportunities for research in a paper recently published in Transfusion Medicine Review, titled “National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: Scientific Opportunities in Extracorporeal Photopheresis.”
“What we know now about ECP is that it is able to function in more than one way,” said Ratcliffe. “It can immunotolerize in the autoreactive setting, and immunize against, in a situation such as lymphoma. This enigma poses tremendous opportunity for future basic science investigation in immunology where cancer applications in bone marrow transplantation and lymphoma will benefit from novel therapeutics.”
Currently, ECP is used to treat cancer patients who have cutaneous T-cell lymphoma or in patients with Graft versus Host disease after transplantation. There are many questions about how the therapy works and the best schedules for treating patients.
In the case of ECP, investigators’ expanding knowledge of the basic science of immunology is on track to intersect with and inform the questions clinicians have about how best to use the power of ECP to treat patients.
“Like with any emerging therapy, support is essential for the combination of bench science, robust animal models, and clinical trials to drive important strategies like extracorporeal photopherisis forward,” Ratcliffe said.
Ratcliffe’s collaborators include NM Dunbar, J Adamski, D Couriel, R Edelson, CL Kitko, JE Levine, S Morgan, J Schneiderman, S Sloan, Y Wu, ZM Szczepiorkowski, L Cooling and they are from the American Society for Apheresis; Department of Pathology and Laboratory Medicine, Department of Veterans Affairs, White River Junction, VT; Transfusion Medicine, Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH; Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ; Hematology-Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI; Department of Dermatology, Yale University School of Medicine, New Haven, CT; Blood and Marrow Transplant Program, University of Michigan, Ann Arbor, MI; Transfusion Medicine Division, Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN; Therapeutic Apheresis Program, Department of Hematology/Oncology/Stem Cell Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL; Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA; Puget Sound Blood Center, Seattle, WA; Blood Bank and Transfusion Services, Department of Pathology, University of Michigan, Ann Arbor, MI
About Norris Cotton Cancer Center at Dartmouth-Hitchcock Norris Cotton Cancer Center combines advanced cancer research at Dartmouth and the Geisel School of Medicine with patient-centered cancer care provided at Dartmouth-Hitchcock Medical Center, at Dartmouth-Hitchcock regional locations in Manchester, Nashua, and Keene, NH, and St. Johnsbury, VT, and at 12 partner hospitals throughout New Hampshire and Vermont. It is one of 41 centers nationwide to earn the National Cancer Institute’s “Comprehensive Cancer Center” designation. Learn more about Norris Cotton Cancer Center research, programs, and clinical trials online at cancer.dartmouth.edu.
RSS